Behzad Bidadi

426 total citations
23 papers, 96 citations indexed

About

Behzad Bidadi is a scholar working on Otorhinolaryngology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Behzad Bidadi has authored 23 papers receiving a total of 96 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Otorhinolaryngology, 13 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Behzad Bidadi's work include Head and Neck Cancer Studies (18 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cancer Diagnosis and Treatment (7 papers). Behzad Bidadi is often cited by papers focused on Head and Neck Cancer Studies (18 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cancer Diagnosis and Treatment (7 papers). Behzad Bidadi collaborates with scholars based in United States, Australia and Japan. Behzad Bidadi's co-authors include Ezra E.W. Cohen, Ramona F. Swaby, Joy Yang Ge, Liewei Wang, Alexander Hein, Duan Liu, Matthias Rübner, Wolfgang Janni, Stéphane Temam and Irene Braña and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Behzad Bidadi

17 papers receiving 95 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Behzad Bidadi United States	5	62	50	42	22	15	23	96
Wei-Han Hu China	4	53 0.9×	85 1.7×	46 1.1×	49 2.2×	14 0.9×	6	118
Michaela K. Keck United States	6	54 0.9×	59 1.2×	43 1.0×	18 0.8×	32 2.1×	13	106
Sophie Wildsmith United Kingdom	7	86 1.4×	32 0.6×	36 0.9×	33 1.5×	12 0.8×	13	101
Xuping Xi China	5	30 0.5×	59 1.2×	37 0.9×	16 0.7×	26 1.7×	9	96
Gustavo Dix Junqueira Pinto Brazil	4	50 0.8×	19 0.4×	45 1.1×	12 0.5×	12 0.8×	5	84
Xinglai Feng China	7	59 1.0×	54 1.1×	20 0.5×	35 1.6×	8 0.5×	12	102
A Murias Spain	6	86 1.4×	15 0.3×	52 1.2×	19 0.9×	13 0.9×	17	123
Sanchit Trivedi United States	4	58 0.9×	34 0.7×	24 0.6×	49 2.2×	28 1.9×	9	102
C. Rossetto Italy	6	70 1.1×	78 1.6×	72 1.7×	52 2.4×	30 2.0×	16	136
Wen-Hui Chen China	5	57 0.9×	44 0.9×	14 0.3×	30 1.4×	42 2.8×	8	124

Countries citing papers authored by Behzad Bidadi

Since Specialization

Citations

This map shows the geographic impact of Behzad Bidadi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Behzad Bidadi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Behzad Bidadi more than expected).

Fields of papers citing papers by Behzad Bidadi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Behzad Bidadi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Behzad Bidadi. The network helps show where Behzad Bidadi may publish in the future.

Co-authorship network of co-authors of Behzad Bidadi

This figure shows the co-authorship network connecting the top 25 collaborators of Behzad Bidadi. A scholar is included among the top collaborators of Behzad Bidadi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Behzad Bidadi. Behzad Bidadi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Su, Behzad Bidadi, Yan Song, et al.. (2025). Real-world treatment patterns and clinical outcomes among elderly patients with locoregionally advanced head and neck squamous cell carcinoma in the United States. Frontiers in Oncology. 15. 1606990–1606990.

Tao, Yungan, Lillian L. Siu, Lisa Licitra, et al.. (2025). Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC).. Journal of Clinical Oncology. 43(16_suppl). 6013–6013. 2 indexed citations

Zhang, Su, Behzad Bidadi, Yuexin Tang, et al.. (2025). Real-world recurrence and survival in locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) treated with surgery and adjuvant radiotherapy with or without systemic therapy: A SEER-Medicare analysis.. JCO Oncology Practice. 21(10_suppl). 546–546.

Ma, Jiemin, et al.. (2025). Incidence and overall survival of head and neck squamous cell carcinoma in the US: SEER 17, 2018-2021.. Journal of Clinical Oncology. 43(16_suppl).

Zheng, Deyou, Christopher M. Black, Behzad Bidadi, et al.. (2024). Sequential Treatment Use in Clinical Practice for U.S. Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC). International Journal of Radiation Oncology*Biology*Physics. 118(5). e34–e34.

Black, Christopher M., Gleicy M. Hair, Lei Ai, et al.. (2024). Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma. Frontiers in Oncology. 14. 1348045–1348045. 4 indexed citations

Machiels, J.-P., Barbara Burtness, Makoto Tahara, et al.. (2024). Health-Related Quality of Life (HRQoL) Data From KEYNOTE-412: Chemoradiotherapy (CRT) with or Without Pembrolizumab (pembro) in Patients (pts) with Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC). International Journal of Radiation Oncology*Biology*Physics. 118(5). e39–e40.

Zhang, Su, Behzad Bidadi, Yan Song, et al.. (2024). Real-world treatment patterns and overall survival (OS) in locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) in the U.S.. Journal of Clinical Oncology. 42(16_suppl). e23275–e23275. 1 indexed citations

Zhang, Su, Behzad Bidadi, Yan Song, et al.. (2024). Real-world event-free survival (rwEFS) and overall survival (rwOS) in elderly patients with resected locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) in the US.. JCO Oncology Practice. 20(10_suppl). 375–375. 1 indexed citations

10.

Harrington, Kevin J., Ezra E.W. Cohen, L.L. Siu, et al.. (2022). Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy. International Journal of Radiation Oncology*Biology*Physics. 112(5). e43–e44. 2 indexed citations

11.

Harrington, Kevin J., Ezra E.W. Cohen, Lillian L. Siu, et al.. (2021). P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. Oral Oncology. 118. 10–11. 1 indexed citations

12.

Gaspar, Nathalie, Quentin Campbell‐Hewson, Stefan Bielack, et al.. (2020). 1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082). Annals of Oncology. 31. S990–S991. 2 indexed citations

13.

Harrington, Kevin J., Ezra E.W. Cohen, L.L. Siu, et al.. (2020). 351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. SHILAP Revista de lepidopterología. A214.1–A214. 2 indexed citations

14.

Uppaluri, Ravindra, Nancy Y. Lee, William H. Westra, et al.. (2019). KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.. Journal of Clinical Oncology. 37(15_suppl). TPS6090–TPS6090. 32 indexed citations

15.

Cohen, Ezra E.W., Ravindra Uppaluri, William H. Westra, et al.. (2019). Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study. Annals of Oncology. 30. ix106–ix106. 4 indexed citations

16.

Bidadi, Behzad, Duan Liu, Krishna R. Kalari, et al.. (2018). Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. Frontiers in Pharmacology. 9. 158–158. 19 indexed citations

17.

Siu, Lillian L., Lisa Licitra, Chia‐Jui Yen, et al.. (2018). Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma. Cancer Research. 78(13_Supplement). CT163–CT163. 4 indexed citations

18.

Machiels, J.-P., Lisa Licitra, Yungan Tao, et al.. (2018). KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 29. viii398–viii398. 4 indexed citations

19.

Machiels, J-P., C-J. Yen, Lisa Licitra, et al.. (2017). Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Annals of Oncology. 28. xi28–xi28.

20.

Bidadi, Behzad, et al.. (2016). Neonatal renal vein thrombosis: Role of anticoagulation and thrombolysis—An institutional review. Pediatric Hematology and Oncology. 33(1). 59–66. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact